Workshop 1- Are IPOs still an attractive alternative for capitalizing your life science company?
15 September 2016
•
S27
•
08:30
>
09:30
•
Workshop 1- Are IPOs still an attractive alternative for capitalizing your life science company?
•
Conference Room 35-36
Hosted by Nasdaq OMX and co-hosted by Davis Polk & Wardwell and Trout Group
This session will describe the current IPO climate, the required steps and procedures in the planning phase, the key ingredients in executing a successful IPO, the advantages and disadvantages of a Nordic/EU vs US listing, as well as whether an IPO is the strongest alternative right now or if there are other more suitable alternatives and how to assess these.
Ms. Sophia Hudson, Partner Capital Markets, Davis & Polk & Wardwell
Mr. Michael K. Levitan, Managing Director, Trout Group
Mr. Adam Kostyál, Senior Vice President, Nasdaq
Mr. Jacob Gunterberg, Partner, HealthCap
Mr. Homan Panahi, CEO, Vator Securities
Mr. Jonas Hansson, CEO, Wilson Therapeutics
|